NDC product
BOTOX
NDC 0023-1145 · Allergan, Inc.
Key facts
| Product NDC | 0023-1145 |
|---|---|
| Proprietary name | BOTOX |
| Nonproprietary name | onabotulinumtoxinA |
| Substances | BOTULINUM TOXIN TYPE A |
| Dosage form | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION |
| Route | INTRADERMAL, INTRAMUSCULAR |
| Labeler | Allergan, Inc. |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | BLA |
| Application number | BLA103000 |
| Pharmacologic classes | Acetylcholine Release Inhibitor [EPC], Acetylcholine Release Inhibitors [MoA], Neuromuscular Blockade [PE], Neuromuscular Blocker [EPC] |
| Marketing start | Dec 15, 1989 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: